Tamoxifen in the treatment of recurrent ovarian carcinoma
Related Experiment Videos
1Deparment of Gynecologic Oncology, The Norwegian Radium Hospital, Montebello, N-310, Oslo, Norway. claes.trope@klinmed.uio.no
Abstract:
This review examines the evidence for useful clinical activity of tamoxifen in women with ovarian carcinoma who have failed conventional cytotoxic chemotherapy. The optimised search strategy of the Cochrane Gynaecological Cancer Collaborative Review Group by Williams was used. Tamoxifen demonstrates a modest degree of effectiveness in ovarian cancer refractory to cytotoxic chemotherapy. The overall objective response rate in all trials (647 patients) was approximately 11%. There is, however, a wide variation in the objective response rates in the different trials (0-56%). Tamoxifen therapy has limited efficacy in refractory ovarian carcinoma. However, considering the mild toxicity of tamoxifen, occasional long-term palliation and lack of alternatives, the drug has a useful role in heavily pretreated patients with ovarian cancer.
Related Concept Videos
Treatment Resistant Cancers
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists